Antimicrobial Resistance in Neisseria gonorrhoeae: Surveillance, Molecular Diagnosis and Point-of-care Tests, Mechanisms of Resistance

A special issue of Antibiotics (ISSN 2079-6382).

Deadline for manuscript submissions: closed (31 May 2021) | Viewed by 7094

Special Issue Editors


E-Mail Website
Guest Editor
Department of Biochemistry, Microbiology and Immunology, College of Medicine, c/o 120 Veterinary Road, Saskatoon, SK S7N 5E3, Canada
Interests: Neisseria gonorrhoeae; antimicrobial resistance; molecular epidemiology; diagnostics
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Veterinary Public Health and Epidemiology, DGCN College of Veterinary and Animal Sciences, Himachal Pradesh Agricultural University, Palampur 176062, Himcahal Pradesh, India
Interests: antimicrobial resistance; Neisseria gonorrhoeae; veterinary public health; zoonoses; food borne pathogens

Special Issue Information

Dear Colleagues,

The prevalence of infections caused by Neisseria gonorrhoeae is rising globally. Coupled with this rise, the ever-present possibility that gonococcal infections will be untreatable in the future has resulted in increased attention by public health agencies worldwide to diagnose infections quickly and to ensure that patients are treated with effective antibiotics.

Over the past 70 years, different antibiotics have been introduced to treat gonococcal infections. N. gonorrhoeae has steadily developed an array of resistance mechanisms to each antibiotic. This has resulted in the successive withdrawal of older antibiotics when resistance in gonococcal populations (>5 percent resistant) precludes their effective use. Choices for effective treatment of gonococcal infections are now severely limited. Presently, therapy with an injectable third-generation cephaloporin coupled with azithromycin is the globally-recommended treatment for uncomplicated gonococcal infections. Resistance to both of these antibiotics has been reported, along with treatment failure using dual therapy.

This Special Issue will seek to highlight the most recent information and advances on antimicrobial-resistant N. gonorrhoeae. This issue will highlight ways to to combat drug resistance through the development and validation of simple, inexpensive, and rapid diagnostics (point-of-care tests) for gonorrhea and its antimicrobial resistance. We will profile regions implementing the Gonococcal Antimicrobial Surveillance Programs (GASP) which are establish local and regional antimicrobial resistance profiles to advise on treatment regimens which reflect local conditions. This issue will also highlight reports on the molecular epidemiology of resistant N. gonorrhoeae isolates to ascertain the dispersal of common resistant strains and the introduction of new phenotypes. In this Special Issue, we hope to highlight advances that lead to a better understanding of mechanisms of AMR in N. gonorrhoeae as well as the evaluation of new antimicrobial agents or antimicrobial combinations.

This Special Issue should serve to highlight the most recent advances in gonococcal AMR topics, including reports from middle and low income countries seeking to better understand the public health issues posed by resistant N. Gonorrhoeae.

Prof. Jo-Anne R. Dillon
Dr. Sidharath Dev Thakur
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Neisseria gonorrhoeae
  • antimicrobial susceptibility
  • molecular epidemiology
  • mechanisms of resistance
  • molecular AMR tests
  • point-of-care tests
  • new AMS technologies, new antimicrobials

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

22 pages, 2824 KiB  
Article
Trends in Antimicrobial Resistance Patterns in Neisseria Gonorrhoeae in Australia and New Zealand: A Meta-analysis and Systematic Review
by Stephanie Fletcher-Lartey, Mithilesh Dronavalli, Kate Alexander, Sayontonee Ghosh, Leng Boonwaat, Jane Thomas, Amanda Robinson, Zeel Patel, Bradley Forssman and Naru Pal
Antibiotics 2019, 8(4), 191; https://doi.org/10.3390/antibiotics8040191 - 23 Oct 2019
Cited by 11 | Viewed by 6131
Abstract
(1) Background: The widespread development of resistance among Neisseria gonorrhoeae (NG) clinical isolates has been reported by surveillance systems around the world. This meta-analysis estimated the changes in susceptibility patterns among antibiotics under surveillance in Australia and New Zealand. (2) Methods: Articles published [...] Read more.
(1) Background: The widespread development of resistance among Neisseria gonorrhoeae (NG) clinical isolates has been reported by surveillance systems around the world. This meta-analysis estimated the changes in susceptibility patterns among antibiotics under surveillance in Australia and New Zealand. (2) Methods: Articles published in English from 1980–2018, from Australia or New Zealand, that met the selection criteria were included. The meta-analysis was carried out using the R statistical software. (3) Results: In Australia, there has been decreasing susceptibility of gonococcal isolates to selected antimicrobials over time. Azithromycin (Odds Ratio (OR): 0.73; 95% Confidence Interval (CI) 0.64–0.82) and ceftriaxone (OR: 0.69; 95% CI 0.59–0.80) showed decreasing levels of susceptibility each year. Western Australia (OR: 0.76; 95% CI 0.60–0.96) and Victoria (OR: 0.74; 95% CI 0.60–0.90) also had decreasing levels of susceptibility to ceftriaxone over time compared with other states and territories. (4) Conclusions: The results highlight the need for the development of new approaches for managing cases of gonorrhoea. Improved antimicrobial stewardship, enhanced surveillance and contact tracing are needed to identify and respond to changes in antibiotic resistance in a timely manner. Increasing awareness and public health follow-up of cases can help to interrupt the cycle of infection and limit transmission. Full article
Show Figures

Graphical abstract

Back to TopTop